- Covaxin in Punjab and Kerala freezers till phase-3 trial resultsSpeaking to ET, Punjab health minister Balbir Singh Sidhu said: “We don’t want to deploy the vaccine right away. Our expert panel of doctors has decided that we will first exhaust 4 lakh doses of Covishield. By then, the data for phase-3 trials would be available and Covaxin would be deployed.”
- Covaxin rolled out in West Bengal, 60 beneficiaries to be inoculated on first day"Everyone receiving Covaxin doses are required to sign an informed consent form. Today, a total of 60 beneficiaries at the three sites will be administered this vaccine. We do not want to take any chance. Slowly and slowly, we will speed up the process," the official told .
- No data generated with Covishield, Covaxin on 'European' strain of coronavirus, Rajya Sabha toldTo a question on whether the Covishield and Covaxin are able to provide protection from the new coronavirus variant that was traced in the UK, Choubey told Rajya Sabha, "At present, there is no data generated with the above vaccines specifically on new European COVID-19 virus strain."
- No serious adverse events in Covaxin Phase 1 trialsBharat Biotech's indigenously developed Covid-19 vaccine, Covaxin, was well tolerated and did not report any serious adverse events during the study conducted in phase 1 trials, as per results published in The Lancet, the prestigious British medical journal.
- Covaxin is successful in tackling UK strain: ICMR DG Balram BhargavaIndian Council of Medical Research DG, Balram Bhargava announced that the Covaxin is successful in tackling UK strain. He further informed that UK variant strain is now present in 70 countries and 164 cases have been identified in India. “UK variant strain is now present in 70 countries and we've identified 164 cases of it in India. We were able to find the first case of the UK variant on 22nd-23rd December. In a week's time, we were able to collect blood from these patients and culture the strain. We found that the neutralisation of UK strain was equivalent to Indian strains circulating in India. It's a very reassuring news that UK variant can be tackled by this vaccine,” informed ICMR DG during a press briefing on January 28. Covaxin is successful in tackling UK strain: ICMR DG Balram Bhargava
- Healthcare NGO raises concerns over CovaxinA day before India begins the world’s largest Covid-19 vaccination drive, a group of healthcare-focused NGOs has sought clarifications from the government on the approval given to Bharat Biotech’s Covaxin.
- Covaxin a hard sell in two of India’s largest hospitalsVaccine hesitancy has hit two of India’s largest state-run hospitals — JJ Hospital in Mumbai and the All-India Institute of Medical Sciences in New Delhi, where Covaxin is being administered.
- Clinical trials indicate India's vaccines will be effective against COVID-19 variants, says ICMRAddressing an international webinar "Kerala Health: Making the SDG A Reality," organised by the Department of Health and Family Welfare, Government of Kerala, Dr Balram Bhargava, Director General of ICMR said a paper on Covaxin's neutralisation potential against the UK strain has been accepted for publication.
- Government panel to meet today to examine widening dosage gap of CovishieldAt present, India is giving the second dose of Covishield after a gap of 28 days. However, new evidence suggests that efficacy is better when the second dose is given after 8-12 weeks.
- Taking Stock: India's Covid vaccine supplies exceed usageHealth ministry data on vaccine supplies between January 16 and February 9 shows that so far only 31.45% of Covishield and 11.75% of Covaxin dispatched stocks have been administered to healthcare providers, defence personnel and frontline workers.
- People above 50 years could be vaccinated in March: Harsh Vardhan, Health MinisterUnion Health Minister Harsh Vardhan held a press conference on February 15 and said, “We are in stage where we provided COVID-19 vaccines to 20-25 countries in the world. We will be in a situation to administer vaccines to those above 50 years of age in March. 80-85% frontline workers vaccinated, 20-25 countries to be availed with vaccine. At least 18-20 vaccines are in preclinical, clinical and advanced stages.”People above 50 years could be vaccinated in March: Harsh Vardhan, Health Minister
- About 18-19 vaccine candidates against COVID-19 in pipeline: Harsh Vardhan"About 18-20 vaccine candidates against COVID-19 are in the pipeline and are in preclinical, clinical and advanced stages," Vardhan said. He further said that India will be supplying vaccines to 20-25 other countries.
- Telangana yet to use Covaxin; inoculation underway in 324 sitesThe official said on the second day that Serum Institute's Covishield will be administered as Bharat Biotech's Covaxin is yet to be dispatched to the centres. Telangana received 20,000 doses of the Covaxin as against 3.64 lakh of Covishied.
- Vaccine antibodies will last at least 8 months: AIIMS chiefDr Guleria added that after two doses, “you are protected. But protecting others would need you to follow Covid-appropriate behaviour”. He said people above 50 years of age and those between 20 and 50 years but with co-morbidities will start getting the vaccine from March.
- India, pharmacy of the world, falls behind on Covid vaccinations at homeIn four weeks health workers vaccinated only 7.5 million frontline workers on priority, a rate at which it would take India several years to reach its goal.
- Now, Covaxin to be tested on toddlers as young as 2 yearsCovaxin, being developed by Bharat Biotech in collaboration with Indian Council of Medical Research and National Institute of Virology, was the first Covid-19 vaccine to begin testing (in September) on children.
- Covishield and Covaxin: Key concerns over the two vaccinesET tries to clear some concerns around the development with experts’ views on how the two vaccines can be used for India’s public vaccination drive, the historical perspective and the challenges ahead.
- India should scale up vaccination ten times to meet targets, say expertsHealth experts have urged the government to rope in private healthcare institutes and corporates to expand the vaccination drive, and delay the second dose of vaccine if necessary.
- Covaxin arrives in Delhi; 20,000 doses to reach Rajiv Gandhi HospitalAfter acquiring Covishield, Rajiv Gandhi Super Speciality Hospital (RGSSH) would now receive 20,000 doses of Bharat Biotech's Covid vaccine from a consignment which landed at the Indira Gandhi International Airport (IGIA) here on Wednesday morning.
- After Covishield, Bharat Biotech's Covaxin arrives in New DelhiBharat Biotech's Covaxin arrives in New Delhi. This comes a day after Serum Institute's Covishield also was sent across the nation for the vaccination drive beginning on Jan 16. Details by Madhavdas G.After Covishield, Bharat Biotech's Covaxin arrives in New Delhi
- Expert panel to submit report soon on priority individual for COVID vaxPaul, who is also the chairman of the National Expert Group On Vaccine Administration for COVID-19 (NEGVAC) said this committee has gone deeply into it and looked at which comorbidities -- the presence of two or more diseases or medical conditions in a patient -- should be kept in mind.
- No provision of insurance for recipients of COVID-19 vaccine: Ashwini Choubey, MoS for HealthMeasures have been put in place like availability of anaphylaxis kits at each vaccination site, immediate referral to AEFI management centre and observation of vaccine recipients for 30 minutes at session site for any adverse events so as to ensure timely corrective measure, Choubey said in a written reply.
- Andhra Pradesh gets 4.96 lakh doses of CovaxinState Health Commissioner Katamaneni Bhaskar said the first consignment of vaccine doses would be sufficient to vaccinate about 3.7 lakh health care workers in the first round beginning January 16.
- Covid vaccination: Just 8,500 of 44 lakh recipients reported adverse eventsData received from respondents show 97.4% said there was adequate social distancing at the booths, 98.4% had been informed about the process, 97.1% were asked to wait for 30 minutes after vaccination and 97.4% were satisfied with the experience.
- 13,000 volunteers administered 2nd dose of Covaxin in phase-3 trials: Bharat BiotechCovaxin is India's totally indigenous COVID-19 vaccine developed in collaboration with the Indian Council of Medical Research and National Institute of Virology.
- Bharat Biotech’s consent forms 'must' for Covaxin shot; What does the form say?As India has begun the COVID vaccine drive, the process of getting vaccinated by Bharat Biotech’s Covaxin is different, one has to sign a consent form before getting the vaccine shot. Mirror Now explains the procedure and the process of getting the vaccination. The form explains that Covaxin has been approved for restricted use in emergency situations and it has the ability to produce antibodies in phase 1, and 2 trials established. The form further says that the efficacy is being studied in phase 3 trials and it is yet to be established. The form also says that receiving the vaccine does not mean COVID norms need not be followed.Bharat Biotech’s consent forms 'must' for Covaxin shot; What does the form say?
- India’s Covaxin led to tolerable safety outcomes and enhanced immune responses: LancetAccording to the Lancet, all adverse events were mild and moderate and were more frequent after the first dose.
- Criticism mounts of India's 'abrupt' approval for Bharat Biotech's CovaxinThe recommendations of the Indian drugs regulator's subject expert committee (SEC) released on Tuesday show that the panel asked Bharat Biotech International Ltd to present more efficacy data for its COVID-19 shot before it could consider approving the treatment.
- SEC recommends Bharat Biotech’s Covaxin for emergency useThe Drug Controller General of India (DCGI) will give the final approval to both the vaccine candidates.
- No approval for Covaxin, expert panel seeks more data from Bharat BiotechEarlier on Friday, the expert committee, which is tasked with vetting covid-19 vaccine proposals, recommended emergency licensure for the Serum Institute of India-manufactured 'Covishield'. It become the first vaccine to secure recommendation for emergency use in India.
- Initiate COVID-19 vaccination of frontline workers from first week of February: Centre to statesIn the letter, Health Ministry Additional Secretary Manohar Agnani said the database of frontline workers is being updated by states and UTs in collaboration with the respective line ministries.
- COVID vaccine: Group of 49 scientists, doctors support of Covaxin & Covishield, slam doubters2 days to go for world’s largest vaccination drive to begin. As the hospitals are preparing for the vaccination drive's first phase, the opposition continues to cast aspersions on Covaxin, which was given emergency use authorization by the DCGI. A group of 49 doctors and scientists have now come out and issued a statement in the favor of both COVID vaccines. The group of doctors has further cited their reasons as well for this. The doctors have even slammed the misinformation that is being put out in regards to the vaccine. COVID vaccine: Group of 49 scientists, doctors support of Covaxin & Covishield, slam doubters
- 'Next-gen' COVID-19 vaccines may be needed to tackle emerging variants, say scientistsWork on vaccines will have to continue on parallel tracks - one to tackle the SARS-CoV-2 virus with first generation vaccines and the other to prepare for possible mutations and new variants - say experts as they map the future course of the infection.
- India has plenty of Coronavirus vaccines but few takersAs India rolls out one of the world’s biggest inoculation programs, some health-care and other frontline workers are hesitating because of safety concerns over a vaccine that has yet to complete phase III trials.
- AIIMS New Delhi advertises for Phase-III clinical trial of Covaxin"AIIMS, New Delhi is a site for COVAXIN Phase III clinical trial. This is a whole-virion inactivated vaccine co-sponsored by Indian Council of Medical Research (ICMR) and Bharat Biotech," AIIMS said in an advertisement.
- Odisha exceeds Covid vaccination target; Sikkim, Lakshadweep beat target tooOdisha had to cover 1,10,387 beneficiaries in the first week of public immunisation drive till Friday. The state covered 1,13,623 beneficiaries – an achievement of 102.9% of the planned beneficiaries. Odisha is one of the 11 states to receive both the vaccines Covaxin and Covishield.
- Vaccine hesitancy will slowly go away, says virologist Dr Shahid JameelWhat should come out in public in clear terms is that both the vaccines are proving to be safe. Even though the efficacy data is not out yet, safety data is out and both vaccines are found to be safe. Now whether it will protect 80% of the population or more or less, we don’t know, says Dr Jameel.
- Bharat Biotech seeks DCGI nod for Covaxin use“After Pfizer and Serum Institute of India, Bharat Biotech has also applied to the drug regulator for market authorisation approval now,” sources confirmed ET.
- Covid-19: States look for ways to immunise the reluctant onesState governments have come up with different strategies to tackle vaccine hesitancy. Apart from the usual appeals from state health ministers and administrative machinery that vaccines are safe, the states have identified Covid warriors who would be inoculated to dispel any fears.
- Covaxin approval row: ICMR chief says Indian rules allow restricted nod without efficacy dataIn a pandemic situation, restricted emergency use of vaccines is considered based on safety and immunogenicity data while phase three clinical trial is underway, Indian Council of Medical Research (ICMR) chief Balram Bhargava said on Tuesday. Explaining the process followed in granting nod to Oxford COVID-19 vaccine and indigenously developed Covaxin, he said, "The existing pandemic situation, high mortality, available science and lack of definitive treatments were considered by the subject expert committee (SEC) on COVID-19 of CDSCO for granting accelerated approval to these vaccines, and that is in our legal provision."Covaxin approval row: ICMR chief says Indian rules allow restricted nod without efficacy data
- COVID vaccine approval row: Bharat Biotech defends Covaxin after backlash over lack of dataAmid growing concerns over the indigenous coronavirus vaccine developed by Hyderabad-based Bharat Biotech, the company’s CMD Krishna Ella today asserted that the clinical trials have been conducted globally over a period of time and it is one of the safest vaccine makers. He also hailed the decision of DCGI to approve Covaxin for emergency restricted use and termed it as a giant leap for innovation and novel product development in India. COVID vaccine approval row: Bharat Biotech defends Covaxin after backlash over lack of data
- Bharat Biotech's Covaxin gets Subject Expert Committee (SEC) approval for emergency useA day after the Subject Expert Committee gave a go-ahead to SII, Oxford-Astrazeneca vaccine candidate-Covishield, the expert panel today recommended Bharat Biotech’s Covaxin too for restricted emergency use, government sources have confirmed. The Drug Controller General of India (DCGI) will give the final approval to both the vaccine candidates.Bharat Biotech's Covaxin gets Subject Expert Committee (SEC) approval for emergency use
- 2,24,301 beneficiaries given vaccine so far; 447 cases of adverse effect reported: Health MinistryHealth Ministry's Additional Secretary Manohar Agnani said a total of 2,24,301 beneficiaries have been vaccinated till January 17 as per provisional reports, adding that 2,07,229 of them received the jabs on day one of the drive.
- Vaccination Day 1: 'Wait and watch' approach, CoWin app snags blamed for 53% turnout in DelhiPeople adopting a "wait and watch" approach, lack of communication and glitches in CoWin app are the major reasons why only 53 per cent people got the COVID-19 shots on the first day in Delhi, experts said on Sunday.
- India's jumbo-sized vaccine rollout in numbersOver the coming months, India aims to inoculate around a quarter of its population, or 30 crore people. They include healthcare workers, people aged over 50 and those at high risk.
- Group of experts slams critics of India's approval process for COVID vaccinesIn a statement signed by 45 medical professionals and scientists, the group expressed shock at the "irresponsible statements of vested interests" and accused these critics of casting aspersions on Indian experts' integrity by making politicised statements to doubt the recent research in the field of COVID-19 vaccines.
- All vaccines procured in first tranche allocated to states, UT in proportion to health workers database: Health MinistryStates have been advised to organise vaccination sessions taking into account 10 percent reserve/wastage doses and an average of 100 vaccinations per session each day.
- Covaxin likely to be available in first quarter of 2021: Bharat BiotechAs companies across the globe are speeding up to bring an effective COVID vaccine, Bharat Biotech’s Joint Managing Director Suchitra Ella hinted that India’s indigenous Covaxin in the country is likely to be available in the first quarter of next year. Covaxin likely to be available in first quarter of 2021: Bharat Biotech
- Several Indian cities get covid-19 vaccine loads, more on the waySerum Institute vaccines were being transported to Delhi, Kolkata, Chennai, Guwahati, Shillong, Hyderabad, Ahmedabad, Vijayawada, Bhubaneswar, Patna, Bengaluru, Lucknow and Chandigarh, Union aviation minister Hardeep Singh Puri tweeted.
- Health secretary briefs par panel on COVID vaccine's development and distributionThe meeting of the panel is being held days before the start of the countrywide COVID-19 vaccination drive from January 16 in what Prime Minister Narendra Modi has called the world's largest inoculation programme.
- World’s largest Covid vaccination campaign: Here is all you need to knowIndia will start this month a vaccination drive to inoculate about 300 million people against Covid-19, an exercise considered to be one of the largest immunization drives in the world. What will it take to vaccinate a population of this size and who will be involved in this programme? ET’s Divya Rajagopal explains.World’s largest Covid vaccination campaign: Here is all you need to know
- COVID vaccine roll-out: 41 destinations finalised across India for deliveryGovernment has prepared a detailed draft for air transportation of COVID-19 vaccines and the movement of vaccine to different parts of the nation is likely to begin by today or tomorrow. Government has made several mini-hub in the country for transportation of COVID vaccine. "There are total 41 destinations (airports) across the country finalised for delivery of vaccines," sources added.COVID vaccine roll-out: 41 destinations finalised across India for delivery
- Be prepared to receive first supply of COVID-19 vaccine likely to be sent shortly: Centre to states, UTsThe country's drugs regulator on Sunday approved Oxford-AstraZeneca's Covishield and indigenously developed Covaxin of Bharat Biotech for restricted emergency use in the country.
- Covaxin in Punjab and Kerala freezers till phase-3 trial resultsSpeaking to ET, Punjab health minister Balbir Singh Sidhu said: “We don’t want to deploy the vaccine right away. Our expert panel of doctors has decided that we will first exhaust 4 lakh doses of Covishield. By then, the data for phase-3 trials would be available and Covaxin would be deployed.”
- Second national dry run for coronavirus vaccinations set to take place tomorrowAs a simulation of actual execution, another round of mock drill in all 700+ districts of all states/UTs (except UP and Haryana who have already conducted/ will be conducting the dry run in all districts on January 5 and January 7, respectively) is planned on January 8, 2021 to ensure efficient planning and management for vaccine delivery in each district of all states and UTs.
- Bharat Biotech vaccine gets approval for use on teenagers“We will soon start trials on children,” Krishna Ella, chairman and managing director of Bharat Biotech, said at a news conference where the company also defended the emergency approval to its vaccine, Covaxin.
- Approval based on adequate safety data: Bharat BiotechBharat Biotech CEO Krishna Ella said he doesn’t know what the regulator meant when it accorded “emergency use permission under clinical trial mode” for the Bharat Biotech vaccine, branded Covaxin. The company is hoping it can run an open trial by vaccinating people as they go without the need for a placebo.
- Bharat Biotech hits outs at critics, says carried out '200 pc honest' trials of corona vaccineNow that vaccine is being politicized, I want to state very clearly that none of my family members is associated with any political party, said Dr Krishna Ella, the founder and chairman of Bharat Biotech,
- View: India’s vaccine nationalism is a global riskTo be sure, India is not even in the front row of vaccine nationalism. China and Russia are more desperate to beat the West in saving the world. But both countries’ candidates face transparency deficit, which could limit their global acceptance. That’s a risk that India, which makes more than 60% of the world’s vaccines, should avoid at all cost.
- Phase-3 trial of Bharat Biotech's Covaxin commences in AIIMSDr Srivastava was the first one to receive the shot, which would be given to around 15,000 volunteers at the AIIMS over the next few days, sources said.
- Fear over Covaxin unfounded, Harsh Vardhan tells ChhattisgarhIn response to Chhattisgarh health minister's letter, health minister says vaccines are safe; vials have expiration date. ET had first reported in its January 28 and February 9 editions that Chhattisgarh would not use Covaxin.
- Chhattisgarh tells centre not to send Covaxin before sharing final trial dataAny wastage of Covaxin would be on you, the state has told the health ministry. Speaking to ET, Chhattisgarh health minister T S Singh Deo said, “We have written to the ministry apprising them of our issues with using Covaxin.
- Bharat Biotech's COVID-19 vaccine "Covaxin" enters phase-3 trialsSpeaking virtually at a programme organised by the Indian School of Business, Ella said the company is also working on another vaccine for COVID-19 which would be in the form of nasal drops and can be ready by next year.
- COVID Vaccine: After Pfizer and Serum Institute, Bharat Biotech applies for emergency use of CovaxinBharat Biotech on Monday applied for emergency use authorisation for its indigenously developed COVID-19 vaccine 'Covaxin' to Drugs Controller General of India (DCGI), officials said. Bharat Biotech is the third company which has applied for emergency use authorisation for its vaccine. It is the second Indian company to apply for emergency use authorisation after the Serum Institute of India applied for such use for a vaccine developed by Oxford University and AstraZeneca. Pfizer had applied for the emergency use authorisation to DCGI on December 6.COVID Vaccine: After Pfizer and Serum Institute, Bharat Biotech applies for emergency use of Covaxin
- How SEC changed Covaxin stanceAt the Jan 2 meeting, the firm presented more data and notably “requested for consideration of their proposal in the wake of incidence of new mutated coronavirus infection.”
- Covid-19: Bharat Biotech, Ocugen ink deal for Covaxin supply to USOcugen Inc and Bharat Biotech on Tuesday announced they have entered into a definitive agreement to co-develop, supply and commercialise Bharat Biotech's Covaxin, an advanced stage whole-virion inactivated Covid-19 vaccine candidate, for the United States market.Covid-19: Bharat Biotech, Ocugen ink deal for Covaxin supply to US
- Bharat Biotech, Ocugen sign pact for supply of Covaxin to US marketThe companies have entered into a definitive agreement for Covaxin, an advanced stage whole-virion inactivated COVID-19 vaccine candidate, for the US market, the companies said.
- Covid vaccination: 11 States say yes to CovaxinRajasthan, Tamil Nadu, Delhi, Maharashtra, Bihar, Karnataka, Odisha, Uttar Pradesh, Assam, Andhra Pradesh and Haryana are the states which have given nod to Covaxin.
- COVID-19 Vaccine: Phase-3 trial of Covaxin begins at Sola Civil Hospital in AhmedabadPhase-3 trial of Covaxin began at Sola Civil Hospital in Gujarat’s Ahmedabad. Volunteers are coming at the hospital for the test. “Volunteers who've been vaccinated have yet not complained of any health issues or symptoms. More volunteers will be vaccinated today,” said Sola Civil Hospital Medical Superintendent Dr Parul Bhatt. Meanwhile, preparation is underway at Serum Institute of India in Pune where Prime Minister Narendra Modi is scheduled to visit on November 28. PM will review the vaccine production.COVID-19 Vaccine: Phase-3 trial of Covaxin begins at Sola Civil Hospital in Ahmedabad
- 1,000 volunteers from Kolkata needed for COVID-19 vaccine - Covaxin - trial at NICEDThe list of 1,000 volunteers will be finalised by the first week of December when the phase III trial is likely to begin.
- Bharat Biotech set to dispatch first consignment of Covaxin"Today in the evening the first consignment is going out of Hyderabad.... (it is from ) Bharat Biotech. It is going to 11 destinations," an official told reporters after receiving the first consignment of Covishield vaccines. Covishield is developed by Oxford University and British-Swedish company AstraZeneca and manufactured by the Serum Institute of India (SII).
- Expert panel reviews EUA application for Sputnik V vaccine; seeks immunogenicity, safety dataDr Reddy's Laboratories on February 19 said it had approached drugs regulator DCGI for emergency use authorisation (EUA) for the Russian vaccine.
- COVID Vaccine: Bharat Biotech's COVAXIN expected to be at least 60% effective, roll-out likely by mid-2021Bharat Biotech, which is manufacturing India’s first indigenous vaccine against COVID-19 today said that the company aims the vaccine to be at least 60 per cent effective after which it is expected to be rolled out mid of 2021. The vaccine rollout is aimed by mid-2021 after approval. The statement has been issued by a senior official from Bharat Biotech and they also said that it is the largest efficacy trials in India.COVID Vaccine: Bharat Biotech's COVAXIN expected to be at least 60% effective, roll-out likely by mid-2021
- Covaxin sent to more states, Chhattisgarh says won’t use it nowChhattisgarh, Jharkhand, Punjab, Gujarat, West Bengal, Kerala and Madhya Pradesh have each received 37,760 doses of Covaxin.
- Reported adverse event during Covaxin phase 1 trial within 24 hours: Bharat BiotechThe statement was issued following a report by Economic Times which revealed that a serious adverse event was seen in a case during the Phase I trial of its indigenous Covid vaccine.
- Covid Vaccine: Expert committee seeks more data from Serum Institute, Bharat Biotech for approvalThe 10-member panel said SII should submit the outcome of the assessment of AstraZeneca-Oxford University trials done by the UK drug regulator. Pfizer seeks more time for presentation.
- CDSCO expert panel seeks more data on COVID-19 vaccines from Serum Institute, Bharat BiotechWhile considering Serum Institute's application, the subject expert committee (SEC) of the CDSCO is learnt to have asked for updated safety data of phase-2 and phase-3 clinical trials in the country, immunogenicity data from the clinical trial in the UK and India, along with the outcome of the assessment of the UK Medicines and Healthcare products Regulatory Agency (MHRA), sources said.
- Bharat Biotech's intranasal COVID-19 vaccine to enter phase 1 trials next monthReplying to a query on the probable pricing of Covaxin, he said Indian vaccines will be much cheaper when compared to other countries.
- Phase 3 trial of Covaxin to begin in Haryana on Nov 20, Anil Vij offers to be first volunteerBharat Biotech had on Monday said the Phase 3 trial of Covaxin will involve 26,000 volunteers across 25 centres in India and is being conducted in partnership with the ICMR. It is the largest clinical trial conducted for a COVID-19 vaccine in India.
- Tamil Nadu Health Minister Dr C Vijayabaskar takes covaxin shot"I got my covaxin shot! Thanks to the team Madras Medical College for the seamless experience. Appeal everyone to do it when your turn comes. Let's end Covid-19 together", Dr C Vijayabaskar tweets.Tamil Nadu Health Minister Dr C Vijayabaskar takes covaxin shot
- Clinical trials indicate India's vaccines will be effective against Covid-19 variants: ICMRDr Bhargava pointed out that India was the fifth country in the world to isolate the Covid-19 virus as part of the efforts to develop a vaccine for the pandemic.
- Explainer: When and how will COVID-19 vaccines become available?Pfizer, with partner BioNTech SE, and rival Moderna have released trial data showing their COVID-19 vaccines to be about 95% effective at preventing the illness, while AstraZeneca last month said its vaccine was on average about 70% effective.
- Can our coronavirus vaccine fight new strains? India to testThe ICMR had announced on Tuesday that Pune-based National Institute of Virology was in the process of isolating and culturing the South African variant in its lab. The NIV has already readied a culture of the Brazilian variant for testing.
- No data on efficacy of India's COVID vaccines against South African, Brazilian variants: ScientistsOn Tuesday, the Health Ministry said four people were detected with the South Africa variant of SARS-CoV-2 and one tested positive for the Brazil variant, a first for India, prompting scientists to stress the need for more data and studies so the country's vaccine programme can be tailored to evolving exigencies.
- Immunocompromised people advised not to take Covaxin: Bharat Biotech releases detailed factsheetBharat Biotech has released a factsheet on its vaccine - Covaxin, and listed out both minor as well as major side effects. Tanima Biswas of MIRROR NOW explains!Immunocompromised people advised not to take Covaxin: Bharat Biotech releases detailed factsheet
- People with fever, pregnant and breastfeeding women avoid Covaxin, says Bharat BiotechThe vaccine maker in the fact sheet on Covaxin, posted in its website, said the clinical efficacy of the vaccine is yet to be established and is being studied in Phase 3 clinical trial and hence it is important to appreciate that receiving the vaccine does not mean other precautions related to COVID- 19 need not be followed.
- India to send Covaxin, Covishield to other nations as goodwill gestureIndia has decided to export 8.1 lakh doses of Covaxin to Oman, Mongolia, Myanmar, Bahrain, Mauritius, the Philippines and the Maldives as a goodwill gesture, people in the know said. Government sources said Serum would supply a few lakh doses of Covishield to the Seychelles, Afghanistan, Bangladesh, Bhutan and Nepal.
- Covid-19 vaccination drive: Speeding up the jab to meet the targetIndia aims to inoculate 300 million over the next three months but needs to pick up the pace and vaccinate at least 3 million a day in the next three months, compared with about 350,000 a day now.
- Chhattisgarh still won't use Covaxin till Phase 3 trial data available: T S Singh DeoA day after health minister Harsh Vardhan wrote to Singh Deo saying fears against Covaxin were unfounded and the state should use both Covaxin and Covishield doses supplied to it, Singh Deo drew parallels with how the Centre had acted “unilaterally” in Goods and Services Tax issue and farm legislations.
- Covid vaccination drive: Many hesitant to sign Covaxin consent formTamil Nadu administered a mere 99 Covaxin doses out of the target of 600 on the first day of the vaccination. On Sunday, the state-administered 90 more Covaxin doses till 2 pm.
- Covid-19 vaccines are coming to India, but are we ready for a rollout?While most experts are confident that India will get a vaccine, their concern is how the country will scale up to vaccinate its 1.3 billion population. This entails, among other things, the requirement of cold chain facilities to store and transport vaccines, training medical staff to administer various types of vaccines, and the cost of the nationwide vaccination exercise.
- Covaxin approval sans due process, alleges Manish Tewari"COVAXIN is another story -- Approvals sans Due Process," the former Union minister added, tagging a media report which claimed scientists and doctors are divided on the issue of restricted use approval granted to the Hyderabad-based Bharat Biotech's Covaxin.
- Resident doctors in RML Hospital want Covishield, express 'apprehension' about Covaxin"The residents are a bit apprehensive about the lack of complete trial in case of Covaxin and might not participate in huge numbers thus defeating the purpose of vaccination. We request you to vaccinate us with Covishield which has completed all stages of trial before its roll-out," the letter stated.
- Bharat Biotech to pay compensation if Covaxin causes side effects"The compensation for serious adverse event will be paid by sponsor (BBIL) in case if the SAE is proven to be causally related to the vaccine," the consent form said.
- Congress states ready for vaccine but puts Covaxin safety onus on CentreCh’garh says will go only for Covishield in first phase, Covaxin after third phase trial
- Second dose of COVID-19 vaccination begins in Tamil NaduHealth Secretary J Radhakrishnan, who inspected the administering of the second dose to healthcare workers at the Government Rajiv Gandhi Government General Hospital here, said the vaccination drive would soon be extended to the public.
- 1,000 volunteers prepare for second dose of CovaxinDr JS Kushwaha, principal investigator at Prakhar hospital, said: "The second dose of Covaxin would also be administered to these 1,000 volunteers from January 3. First dose of this vaccine was given to volunteers from different walks of life."
- Covishield and Covaxin are safe, assures ICMR scientist Dr. Samiran PandaIndian Council of Medical Research, Scientist and Head of Epidemiology and Communicable Diseases Division, while speaking to ANI assured that both Covishield and Covaxin are safe and there should not be an iota of apprehension about its safety. “Both Covishield and Covaxin are safe and there should not be an iota of apprehension about its safety. We should all try to dispel the myths and misconceptions around both vaccines.” Further appreciating India’s scientists, Panda said, “In older days, it would take 20-30 yrs to get a vaccine or medicine out in market. Since knowledge about the whole genome of virus, within10-12 months the vaccine (Covaxin) has come out and it underlines the superiority, ability and commitment of Indian scientists.”Covishield and Covaxin are safe, assures ICMR scientist Dr. Samiran Panda
SubscribeGet APP
- Nifty14,982.00274.20Sensex50,781.691,030.28
- USD/INR72.33-0.12
